A BILL 
To require the Secretary of Health and Human Services 
to establish reference prices for prescription drugs for 
purposes of Federal health programs, and for other pur-
poses. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘End Price Gouging 
4
for Medications Act’’. 
5
01:29 Jun 08, 2021
H2829
2 
•HR 2829 IH
SEC. 2. REFERENCE PRICES FOR PRESCRIPTION DRUGS. 
1
(a) REFERENCE PRICES.—The Secretary of Health 
2
and Human Services (referred to in this section as the 
3
‘‘Secretary’’), in accordance with subsection (b), shall es-
4
tablish annual reference prices for each prescription drug. 
5
Notwithstanding any other provision of law, with respect 
6
to enrollees or beneficiaries in any of the Federal health 
7
programs described in subsection (c), the retail list price 
8
for a drug shall not exceed the reference price for such 
9
drug. 
10
(b) CRITERIA.— 
11
(1) IN
GENERAL.—Each year, the Secretary 
12
shall establish the reference price for each prescrip-
13
tion drug under subsection (a)— 
14
(A) by determining the median retail list 
15
price for the drug among the reference coun-
16
tries in which the drug is available, if drug pric-
17
ing information is available for at least 3 of 
18
such countries; or 
19
(B) in the case of a drug for which drug 
20
pricing information or dosage equivalents are 
21
not available for at least 3 of the reference 
22
countries, by determining an appropriate price 
23
based on the Secretary’s determination of— 
24
(i) the added therapeutic effect of the 
25
drug; 
26
01:29 Jun 08, 2021
H2829
3 
•HR 2829 IH
(ii) the value of the drug; 
1
(iii) patient access to the drug; 
2
(iv) the costs associated with re-
3
searching and developing the drug; and 
4
(v) other factors, as the Secretary de-
5
termines appropriate. 
6
(2) REFERENCE COUNTRIES.—For purposes of 
7
paragraph (1), the reference countries are Japan, 
8
Germany, the United Kingdom, France, Italy, Can-
9
ada, Australia, Spain, the Netherlands, Switzerland, 
10
and Sweden. 
11
(c) FEDERAL HEALTH PROGRAMS.—The reference 
12
prices established under subsection (a) shall apply with re-
13
spect to covered inpatient and outpatient drugs under— 
14
(1) the Medicare program under title XVIII of 
15
the Social Security Act (42 U.S.C. 1395 et seq.); 
16
(2) a State Medicaid plan under title XIX of 
17
the Social Security Act (42 U.S.C. 1396 et seq.); 
18
(3) the State Children’s Health Insurance Pro-
19
gram under title XXI of the Social Security Act (42 
20
U.S.C. 1397aa et seq.); 
21
(4) the TRICARE program under chapter 55 of 
22
title 10, United States Code; 
23
01:29 Jun 08, 2021
H2829
4 
•HR 2829 IH
(5) hospital care and medical services furnished 
1
by the Department of Veterans Affairs under chap-
2
ters 17 and 18 of title 38, United States Code; 
3
(6) the Federal Employees Health Benefits 
4
Program established under chapter 89 of title 5, 
5
United States Code; and 
6
(7) any health program, service, function, activ-
7
ity, or facility funded, in whole or part, under the 
8
Indian Health Care Improvement Act (25 U.S.C. 
9
1601 et seq.), including through direct or contract 
10
care provided under such Act or through a contract 
11
or compact under the Indian Self-Determination and 
12
Education Assistance Act (25 U.S.C. 5304 et seq.). 
13
(d) APPLICABILITY
TO OTHER PURCHASERS
OF 
14
DRUGS.—Notwithstanding any other provision of law, a 
15
drug manufacturer shall offer prescription drugs at the 
16
reference price to all individuals, including individuals who 
17
are not insured and individuals who are covered under a 
18
group health plan or group or individual health insurance 
19
coverage. In the case of individuals covered by a group 
20
health plan or group or individual health insurance cov-
21
erage, such requirement is met if the amount covered 
22
under such plan or coverage plus the cost-sharing amount 
23
does not exceed the reference price. 
24
(e) ENFORCEMENT.— 
25
01:29 Jun 08, 2021
H2829
5 
•HR 2829 IH
(1) CIVIL PENALTY.—A drug manufacturer who 
1
does not comply with the requirements of subsection 
2
(a) shall be subject to a civil penalty, for each year 
3
in which the violation occurs and with respect to 
4
each drug for which the violation occurs, in an 
5
amount equal to 5 times the difference between— 
6
(A) the total amount received by the man-
7
ufacturer for sales of the drug under the Fed-
8
eral health programs under subsection (c) for 
9
the year; less 
10
(B) the total amount the manufacturer 
11
would have received for sales of the drug under 
12
such programs for the year if the manufacturer 
13
had complied with subsection (a). 
14
(2) AMOUNTS
COLLECTED.—Each year, the 
15
Secretary of the Treasury shall transfer to the Di-
16
rector of the National Institutes of Health an 
17
amount equal to the amount collected in civil pen-
18
alties under subsection (e) for the previous year. The 
19
Director of the National Institutes of Health shall 
20
use amounts so transferred for purposes of con-
21
ducting drug research and development. 
22
(f) APPLICABILITY
TO
BRAND
AND
GENERIC 
23
DRUGS.—The reference price established under subsection 
24
(a) shall apply to drugs approved under subsection (c) or 
25
01:29 Jun 08, 2021
H2829
6 
•HR 2829 IH
(j) of section 505 of the Federal Food, Drug, and Cos-
1
metic Act (21 U.S.C. 355) or under subsection (a) or (k) 
2
of section 351 of the Public Health Service Act (42 U.S.C. 
3
262). 
4
Æ 
01:29 Jun 08, 2021
H2829
